论文部分内容阅读
目的:探讨肿瘤标志物联合检测对肝癌早期诊断的价值。方法:汇总原发性肝癌82例和肝硬化44例的AFP(甲胎蛋白)、GP73(高尔基体蛋白73)、AFPL3(甲胎蛋白异质体)、AFPL3/AFP及联合检测结果,结合临床资料进行对比分析。结果:原发性肝癌患者AFP、AFPL3、GP73、AFPL3/AFP阳性率均非常显著高于肝硬化患者(P<0.01);在早期和中期肝癌患者,采用多种肿瘤标志物联合检测,其阳性率非常显著高于各单项检测(P<0.01)。结论:肿瘤标志物联合检测对肝癌早期诊断的价值较高。
Objective: To explore the value of joint detection of tumor markers in the early diagnosis of liver cancer. Methods: AFP (AFP), GP73 (Apoptosis protein73), AFPL3 (AFP), AFPL3 / AFP and the combined detection of 82 cases of primary liver cancer and 44 cases of liver cirrhosis were collected. Data for comparative analysis. Results: The positive rates of AFP, AFPL3, GP73 and AFPL3 / AFP in patients with primary hepatocellular carcinoma were significantly higher than those in cirrhotic patients (P <0.01). In early and middle stage liver cancer patients, the positive rates of AFP, AFPL3, The rates were significantly higher than the individual tests (P <0.01). Conclusion: The combined detection of tumor markers is of great value in the early diagnosis of liver cancer.